Diabetes is a group of metabolic diseases characterized by hyperglycaemia associated with inadequate insulin secretion or poor cells response to insulin. It can affect a large proportion of patients after a kidney transplant. New onset diabetes after transplantation (NODAT) is often associated with the use of immunosuppressive drugs including steroids. However, a significantly greater number of risk factors affect the development of the disease. The occurrence of diabetes after renal transplantation is associated with some limitations in society function and significantly impairs the proper conduct of such patients in outpatient departments. Frequent drug modifications may result in much faster impairment of the grafted kidney function and eventually loss of graft. This work aims to show the essence of the disease, to assess the risk factors of its development, and to show the role of diabetes education to help patient affected by the disease.

kidney transplant; diabetes; owerweight; immunosupression.

Woodward RS, Schnitzler MA, Baty J, et al. (2003). Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant;3:590–598 [PubMed]

Burroughs TE, Swindle J, Takemoto S, et al. (2007). Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation;83:1027–1034 [PubMed]

Hjelmesaeth J, Hartmann A, Leivestad T, et al. (2006). The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int;69:588–595[PubMed]

Konopa J., Orłowska-Kunikowska E., Białobrzeska B. i wsp. (2010). Jak żyć z przeszczepioną nerką. Czelej, Lublin: 120– –129.

Hricik D.E., Anton H.A., Knauss T.C. i wsp. (2002). Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus and corticosteroids. Transplantation; 74: 189–193

Benhamou P.Y., Penformis A. (2002). Natural history, prognosis and management of transplantation induced diabetes mellitus. Diabetes Metab.; 28: 166–175.

Tatoń J., Czech A. (2001). Diabetologia. Wydawnictwo Lekarskie PZWL Warszawa.

Hjelmesaeth J, Hartmann A, Kofstad J, et al. (1997). Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation;64:979–983 [PubMed]

Chakkera HA, Hanson RL, Raza SM, et al. (2009). Pilot study: association of traditional and genetic risk factors and new-onset diabetes mellitus following kidney transplantation. Transplant Proc;41:4172–4177 [PMC free article] [PubMed]

Porrini E, Delgado P, Bigo C, et al. (2006). Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis;48:134–142 [PubMed]

Meier-Kriesche H.V., Arndorfer J.A., Kaplan B. (2002). The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation 73, 70

Van Laecke S, Van Biesen W, Verbeke F, De Bacquer D, Peeters P, Vanholder R. (2009). Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Am J Transplant; 9:2140–2149 [PubMed]

Rodríguez-Morán M, Guerrero-Romero F. (2003). Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care;26:1147–1152 [PubMed]

Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę (2008). Diabetol. Prakt. 9 (Suplement A)

Ghisdal, L., Van Laecke, S., Abramowicz, M. J., Vanholder, R., & Abramowicz, D. (2011). New-onset diabetes after renal transplantation: risk assessment and management. Diabetes care, 35(1), 181-8.

Pascual J, Zamora J, Galeano C, Royuela A, Quereda C. (2009). Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev.

Tamura K, Fujimura T, Tsutsumi T, et al. (1995). Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. Transplantation;59:1606–1613[PubMed]

Maes BD, Kuypers D, Messiaen T, et al. (2001). Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. Transplantation;72:1655–1661 [PubMed]

Wyzgał J., Santorski G. (2008). Cukrzyca po przeszczepieniu narządów. Czelej, Lublin: 8–10.

Johnston O, Rose CL, Webster AC, Gill JS. (2008). Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol;19:1411–1418 [PMC free article] [PubMed]

Genuth S, Alberti KG, Bennett P, et al. ; (2003). Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care;26:3160–3167 [PubMed]

American Diabetes Association Diagnosis and classification of diabetes mellitus. (2010). Diabetes Care;33(Suppl. 1):S62–S69 [PMC free article] [PubMed]

Sharif A, Baboolal K. (2010). Diagnostic application of the A(1c) assay in renal disease. J Am Soc Nephrol;21:383–385 [PMC free article] [PubMed]

International Expert Committee (2009). International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care;32:1327–1334 [PMC free article] [PubMed]

Beata Białobrzeska. (2010). Posttransplant diabetes mellitus in kidney transplant recipients — the role of nurses in complex care for patients. Forum Nefrologiczne. tom 3, nr 4, 311–316